In the first of a four part series we look at how adjacent disciplines view research. David Taylor from Kwittken London provides the first input – from our colleagues in PR.
A review of the recent Kantar Information is Beautiful Awards that includes key learnings and probing questions.
By Ross McKinnon and Talia S. Foster, M.S.
Biosimilars may offer lower-cost versions of existing biologic therapies – but a survey of Japan/Asia/Pacific (JAPAC) clinicians finds some confusion regarding differences between original biologics and biosimilars that may affect patients.
By Kevin Gray and Koen Pauwels
“In spite of our strong marketing support, sales of our brand are flagging. Why? What should we do?”
“If we launch this new product, what will it do to our bottom line? Will we just cannibalize our flagship brand?”
These are just two examples of questions marketers around the world ask themselves every day.